Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NovaBay Pharmaceuticals, Inc. Common Stock (NY: NBY )

0.7176 +0.0075 (+1.06%)
Official Closing Price Updated: 8:00 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 228,063
Open 0.7001
Bid (Size) 0.6820 (11)
Ask (Size) 0.7500 (2)
Prev. Close 0.7101
Today's Range 0.6368 - 0.7200
52wk Range 0.3611 - 9.079
Shares Outstanding 30,098,150
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga

Performance

YTD
+14.82%
+14.82%
1 Month
+26.61%
+26.61%
3 Month
+30.38%
+30.38%
6 Month
+8.73%
+8.73%
1 Year
-87.50%
-87.50%

More News

Read More
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders
From NovaBay Pharmaceuticals
Via Business Wire
NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024
From NovaBay Pharmaceuticals
Via Business Wire
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova Brand
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
What's Going On With NovaBay Pharmaceuticals Shares Friday?
Via Benzinga
NBY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NovaBay Pharmaceuticals, Inc.’s Avenova Brand and Business Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NBY Stock Earnings: NovaBay Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports Record Amazon Prime Day Sales
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
What's Going On With NovaBay Pharmaceuticals (NBY) Stock?
Via Benzinga
NovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering, Including Partial Exercise of Overallotment Option
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
S&P 500 Gains Over 1%; 3M Shares Jump After Q2 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Why NovaBay Pharmaceuticals (NBY) Stock Is Down 60%
Via Benzinga
Crude Oil Down Over 2%; Bristol Myers Squibb Posts Upbeat Q2 Results
Via Benzinga
Exposures Fossil Fuels
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Dow Surges 550 Points; Headline PCE Price Index Falls To 2.5%
Via Benzinga
Topics Stocks
Exposures US Equities
NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.